
**PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA
LIMITED)**

UNAUDITED

ABRIDGED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED)

COMPANY INFORMATION

Directors	Rasha Oudeh (Germany) Fatma Zaki Mohammed Redha Shubbar (Jordan) (appointed 5 April 2024)
Company secretary	Rasha Oudeh (Appointed 5 April 2024) Ahmad Oudeh (Resigned 5 April 2024)
Registered number	651259
Registered office	28 Western Parkway Business Park Lower Ballymount Road Dublin 12 Ireland
Accountants	Crowe Ireland Chartered Accountants 40 Mespil Road Dublin 4

PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED)

CONTENTS

	Page
Accountants' Report	1
Abridged Balance Sheet	2 - 3
Notes to the Abridged Financial Statements	4 - 8

PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED)

CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTORS ON THE UNAUDITED FINANCIAL STATEMENTS OF PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED) FOR THE YEAR ENDED 31 DECEMBER 2024

In order to assist you to fulfil your duties under the Companies Act 2014, we have compiled the financial statements of Pharmotechs Limited (formerly known as Ziltra Pharma Limited) for the year ended 31 December 2024 which comprise the Balance Sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

This report is made solely to the Directors of Pharmotechs Limited (formerly known as Ziltra Pharma Limited) in accordance with the terms of our engagement letter. Our work has been undertaken solely so that we might compile the financial statements of Pharmotechs Limited (formerly known as Ziltra Pharma Limited) that we have been engaged to compile, report to the Company's Board of Directors that we have done so and state those matters that we have agreed to state to the Board of Directors of Pharmotechs Limited (formerly known as Ziltra Pharma Limited), as a body, in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Pharmotechs Limited (formerly known as Ziltra Pharma Limited) and its Board of Directors, as a body, for our work or for this report.

We have carried out this engagement in accordance with technical guidance issued by the Institute of Chartered Accountants in Ireland and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements.

You have acknowledged on the Balance Sheet as at 31 December 2024 your duty to ensure that Pharmotechs Limited (formerly known as Ziltra Pharma Limited) has kept proper accounting records and to prepare financial statements that give a true and fair view under the Companies Act 2014 of Pharmotechs Limited (formerly known as Ziltra Pharma Limited). You consider that Pharmotechs Limited (formerly known as Ziltra Pharma Limited) is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit of the financial statements of Pharmotechs Limited (formerly known as Ziltra Pharma Limited). For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

Crowe Ireland

Chartered Accountants
40 Mespil Road
Dublin 4
Date: 3 December 2025

PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED)

ABRIDGED BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	2024 €	2023 €
Creditors: amounts falling due within one year	5	(6,836)	(4,586)
Net current liabilities		(6,836)	(4,586)
Total assets less current liabilities		(6,836)	(4,586)
Net liabilities		(6,836)	(4,586)
Capital and reserves			
Called up share capital presented as equity		10,000	10,000
Profit and loss account		(16,836)	(14,586)
Shareholders' funds		(6,836)	(4,586)

PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED)

**ABRIDGED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024**

These financial statements have been prepared in accordance with the small companies regime.

We, as Directors of Pharmotechs Limited (formerly known as Ziltra Pharma Limited), state that:

- a) the Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014.
- b) the Company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.
- c) no notice under Subsection (1) of Section 334 has, in accordance with Subsection (2) of that section, been served on the company.
- d) we acknowledge the Company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the state of the assets, liabilities and financial position of the Company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company.
- (e) the Company has relied on the specific exemptions contained in Section 352 of the Companies Act 2014 and the Company has done so on the grounds that it is entitled to benefit from that exemption as a small company and the abridged financial statements have been properly prepared in accordance with Section 353 of the Companies Act 2014.

The financial statements were approved and authorised for issue by the board:

Fatma Zaki Mohammed Redha Shubbar
Director

Rasha Oudeh
Director

Date: 3 December 2025

The notes on pages 4 to 8 form part of these financial statements.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. General information

The financial statements comprising the Profit and Loss Account, the Balance Sheet and the related notes constitute the individual financial statement of Phramotechs Limited for the financial year ended 31 December 2024. The company was known as Ziltra Pharma Limited until 20 March 2024.

Pharmotechs Limited is a private company limited by shares, incorporated and registered in the Republic of Ireland (CRO number 651259). The Registered office is 28 Western Parkway Business Park, Lower Ballymount Road, Dublin 12. The nature of the Company's operations and its principal activities are set out on the Directors' Report.

The financial statements have been presented in the Euro currency (€) which is also the functional currency of the company.

The significant accounting policies adopted by the Company and applied consistently in the preparation of these financial statements are set out as follows:

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared on a going concern basis under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2014.

The company qualifies as a small company for the period, as defined by section 280A of the Act, in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Act and Section 1A of FRS 102.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.2 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

2.3 Unpaid share capital

The share capital of the company issued on incorporation is unpaid and held in trust by the directors. The share capital is measured at cost and the value of shares held in trust is disclosed on the Balance Sheet as Other Debtors.

2.4 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.5 Financial instruments

Ordinary Share Capital

The ordinary share capital of the company is presented as equity.

Cash and cash equivalents

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

Loans and borrowings

All loans made by the company are initially recorded at the amount of cash advanced plus transaction costs incurred, unless the arrangement constitutes, in effect, a financing transaction, in which case it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument. Subsequently loans made by the company are stated at amortised cost using the effective interest rate method less impairment, where there is objective evidence of impairment.

All borrowings by the company, with the exception of loans from directors who are natural persons and shareholders in the company (or close members of the family of such persons), are initially recorded at the amount of cash received less separately incurred transaction costs, unless the arrangement constitutes, in effect, a financing transaction, in which case it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, borrowings are stated at amortised cost using the effective interest rate method.

Loans from directors who are natural persons and shareholders in the company (or close members of the family of such persons) are initially measured at transaction price and not discounted on subsequent measurement.

Other financial liabilities

Other financial liabilities, including trade creditors arising from goods purchased from suppliers on short-term credit, are initially measured at the undiscounted amount owed to the creditor, which is normally the invoice price. Liabilities that are settled within one year are not discounted. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial liabilities are measured at amortised cost.

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

3. Judgments in applying accounting policies and key sources of estimation uncertainty

The preparation of these financial statements require management to make judgements, estimates and assumptions that affect the application of policies amounts of assets, liabilities, income and expenses.

Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Company makes estimates and assumptions concerning the future. The results accounting estimates, will by definition, seldom equal the related actual results. The estimates and assumptions that have significant risk of causing a material adjustment to the carrying amounts of the assets and liabilities within the next financial year are discussed below:

(a) Going concern

The Directors considers it appropriate to prepare the financial statements on a going concern basis.

4. Employees

The average monthly number of employees, including the Directors, during the year was as follows:

	2024	2023
	No.	No.
Directors	2	1
	<u><u>2</u></u>	<u><u>1</u></u>

5. Creditors: Amounts falling due within one year

	2024	2023
	€	€
Amounts owed to group undertakings (Note 6)	1,181	1,181
Accruals	5,655	3,405
	<u><u>6,836</u></u>	<u><u>4,586</u></u>

6. Related party transactions

The Company has taken advantage of the exemption conferred by FRS 102, Section 33 not to disclose transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member.

PHARMOTECHS LIMITED (FORMERLY KNOWN AS ZILTRA PHARMA LIMITED)

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7. Appropriation of Profit & loss account

	2024 €	2023 €
Profit and loss account brought forward at the beginning of the year	(14,586)	(12,336)
Other movement in the profit and loss account	(2,250)	(2,250)
Profit and loss account carried forward at the end of the year	(16,836)	(14,586)